Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review.
Anticonvulsants
Antidepressants
Fibromyalgia syndrome
Personalized therapy
Pharmacological treatment
Journal
Current pain and headache reports
ISSN: 1534-3081
Titre abrégé: Curr Pain Headache Rep
Pays: United States
ID NLM: 100970666
Informations de publication
Date de publication:
23 Jul 2024
23 Jul 2024
Historique:
accepted:
17
05
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
aheadofprint
Résumé
Fibromyalgia Syndrome (FMS) is a complex chronic pain condition characterized by widespread musculoskeletal pain and numerous other debilitating symptoms. The purpose of this review is to provide a comprehensive overview, based on everyday clinical practice, of the drugs presently employed in the treatment of FMS. The treatment of FMS is based on a multimodal approach, with pharmacologic treatment being an essential pillar. The drugs used include tricyclic antidepressants, serotonin and noradrenaline reuptake inhibitors, other antidepressants, anticonvulsants, myorelaxants, and analgesics. The effectiveness of these medications varies, and the choice of drug often depends on the specific symptoms presented by the patient. Many drugs tend to either address only some domains of the complex FMS symptomatology or have a limited effect on pain. Each treatment option comes with potential side effects and risks that necessitate careful consideration. It may be beneficial to divide patients into clinical subpopulations, such as FMS with comorbid depression, for more effective treatment. Despite the complexities and challenges, the pharmacological treatment remains a crucial part for the management of FMS. This review aims to guide clinicians in prescribing pharmacological treatment to individuals with FMS.
Identifiants
pubmed: 39042299
doi: 10.1007/s11916-024-01277-9
pii: 10.1007/s11916-024-01277-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Arnold LM, Bennett RM, Crofford LJ, Dean LE, Clauw DJ, Goldenberg DL, et al. AAPT diagnostic criteria for fibromyalgia. J Pain. 2019;20:611–28. Available from: https://doi.org/10.1016/j.jpain.2018.10.008 .
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol. 2011;38:1113–22.
doi: 10.3899/jrheum.100594
pubmed: 21285161
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. Revisions to the 2010, 2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46:319–29. Available from: https://doi.org/10.1016/j.semarthrit.2016.08.012 .
Sarzi-Puttini P, Giorgi V, Atzeni F, Gorla R, Kosek E, Choy EH, et al. Fibromyalgia position paper. Clin Exp Rheumatol. 2021 May-Jun;39 Suppl 130(3):186-193. https://doi.org/10.55563/clinexprheumatol/i19pig .
Sandström A, Ellerbrock I, Löfgren M, Altawil R, Bileviciute-Ljungar I, Lampa J, et al. Distinct aberrations in cerebral pain processing differentiating patients with fibromyalgia from patients with rheumatoid arthritis. Pain. 2022;163:538. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832547/
Sarzi-puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16:645–660. Available from: https://doi.org/10.1038/s41584-020-00506-w .
Krock E, Morado-Urbina CE, Menezes J, Hunt MA, Sandström A, Kadetoff D, et al. Fibromyalgia patients with elevated levels of anti-satellite glia cell immunoglobulin G antibodies present with more severe symptoms. Pain. 2023;164:1828–40. Available from: https://pubmed.ncbi.nlm.nih.gov/36943275/ . This article is important because it presents pioneering research indicating that a subset of fibromyalgia patients have elevated levels of anti-SGC antibodies, which could potentially pave the way for personalized treatment options targeting these autoantibodies.
Jensen KB, Loitoile R, Kosek E, Petzke F, Carville S, Fransson P, et al. Patients with fibromyalgia display less functional connectivity in the brain’s pain inhibitory network. Mol Pain. 2012;8:32. https://doi.org/10.1186/1744-8069-8-32 .
Ellingsen DM, Beissner F, Moher Alsady T, Lazaridou A, Paschali M, Berry M, et al. A picture is worth a thousand words: linking fibromyalgia pain widespreadness from digital pain drawings with pain catastrophizing and brain cross-network connectivity. Pain. 2021;162:1352–63. Available from: https://pubmed.ncbi.nlm.nih.gov/33230008/ .
Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37:1593–601. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7526868 .
Amin OA, Abouzeid SM, Ali SA, Amin BA, Alswat KA. Clinical association of vitamin D and serotonin levels among patients with fibromyalgia syndrome. Neuropsychiatr Dis Treat. 2019;15:1421–6. Available from: https://www.tandfonline.com/action/journalInformation?journalCode=dndt20 .
Häuser W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther. 2014;16:1–10. Available from: https://arthritis-research.biomedcentral.com/articles/10.1186/ar4441 .
Salaffi F, Di Carlo M, Farah S, Atzeni F, Buskila D, Ablin JN, et al. Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified fibromyalgia assessment status. Rheumatology (Oxford). 2020;59:3042–3049. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32206792 .
Carville S, Constanti M, Kosky N, Stannard C, Wilkinson C. Chronic pain (primary and secondary) in over 16s: summary of NICE guidance. BMJ. 2021;373. Available from: https://www.bmj.com/content/373/bmj.n895 .
Zis P, Daskalaki A, Bountouni I, Sykioti P, Varrassi G, Paladini A. Depression and chronic pain in the elderly: links and management challenges. Clin Interv Aging. 2017;12:709–20. Available from: https://www.dovepress.com/depression-and-chronic-pain-in-the-elderly-links-and-management-challe-peer-reviewed-fulltext-article-CIA .
Ferreira GE, Abdel-Shaheed C, Underwood M, Finnerup NB, Day RO, McLachlan A, et al. Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews. BMJ. 2023;380. Available from: https://www.bmj.com/content/380/bmj-2022-072415 .
Alberti FF, Becker MW, Blatt CR, Ziegelmann PK, da Silva Dal Pizzol T, Pilger D. Comparative efficacy of amitriptyline, duloxetine and pregabalin for treating fibromyalgia in adults: an overview with network meta-analysis. Clin Rheumatol. 2022;41:1965–78. Available from: https://pubmed.ncbi.nlm.nih.gov/35347488/ . This article is significant as it provides a comprehensive evaluation of the efficacy of three different drugs in reducing pain intensity in fibromyalgia patients, offering critical insights for clinical decision-making and patient management.
Häuser W, Wolfe F, Tölle T, Uçeyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs. 2012;26:297–307. Available from: http://link.springer.com/10.2165/11598970-000000000-00000 .
Farag HM, Yunusa I, Goswami H, Sultan I, Doucette JA, Eguale T. Comparison of amitriptyline and US food and drug administration–approved treatments for fibromyalgia: a systematic review and network meta-analysis. JAMA Netw Open. 2022;5:e2212939–e2212939. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792390 .
Yavuzer G, Kapakdeveci A, Arasil T, Elhan A. Moclobemid treatment in primary fibromyalgia syndrome. Eur J Phys Med Rehabil. 1998. Available from: https://www.epistemonikos.org/fr/documents/968fb76a30214a96e7b822b212423f60eb17c8aa .
Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 1998;37:1279–86. Available from: https://pubmed.ncbi.nlm.nih.gov/9973149/ .
Ginsberg F, Joos E, Géczy J, Bruhwyler J, Vandekerckhove K, Famaey JP. A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia. J Musculoskelet Pain. 1998;6:5–17. https://doi.org/10.2165/11595410-000000000-00000 .
doi: 10.2165/11595410-000000000-00000
Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015;16:1347–68.
doi: 10.1517/14656566.2015.1047343
pubmed: 26001183
Walitt B, Urrútia G, Nishishinya MB, Cantrell SE, Häuser W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst Rev. 2015;2015. Available from: https://pubmed.ncbi.nlm.nih.gov/26046493/ .
Liu X, Wang G, Ai G, Xu X, Niu X, Zhang M. Selective ablation of descending serotonin from the rostral ventromedial medulla unmasks its pro-nociceptive role in chemotherapy-induced painful neuropathy. J Pain Res. 2020;13:3081–94. Available from: https://pubmed.ncbi.nlm.nih.gov/33262643/ .
Krupa AJ, Korkosz M, Gorostowicz A, Nowakowski J, Kierzkowska I, Dudek D, et al. Predictors of treatment response to serotonin and noradrenaline reuptake inhibitors in fibromyalgia. Pol Arch Intern Med. 2023;133:16432–16432. Available from: https://europepmc.org/article/med/36799096 . This article is important as it uncovers the associations between insulin resistance, psychiatric comorbidities, and treatment response to SNRIs in patients with fibromyalgia, providing essential insights for personalized patient treatment.
Mascarenhas RO, Souza MB, Oliveira MX, Lacerda AC, Mendonça VA, Henschke N, et al. Association of therapies with reduced pain and improved quality of life in patients with fibromyalgia: a systematic review and meta-analysis. JAMA Intern Med. 2021;181:104–12. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772354 .
Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974–84. Available from: http://doi.wiley.com/10.1002/art.20485 .
Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30:1988–2004. Available from: https://pubmed.ncbi.nlm.nih.gov/19108787/ .
Arnold LM, Palmer RH, Gendreau RM, Chen W. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran. Psychosomatics. 2012;53:371–9. Available from: https://pubmed.ncbi.nlm.nih.gov/22677218/ .
Pickering G, Macian N, Delage N, Picard P, Cardot J-M, Sickout-Arondo S, et al. Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study. Drug Des Devel Ther. 2018;12:2485–96. Available from: https://www.dovepress.com/milnacipran-poorly-modulates-pain-in-patients-suffering-from-fibromyal-peer-reviewed-article-DDDT .
Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009;14:536–46. Available from: https://www.cambridge.org/core/journals/cns-spectrums/article/abs/mechanism-of-action-of-trazodone-a-multifunctional-drug/336DB6B060471BA6C675337CC8AA637C .
Khouzam HR. A review of trazodone use in psychiatric and medical conditions. Postgrad Med. 2017;129:140–8. Available from: https://www.tandfonline.com/doi/abs/10.1080/00325481.2017.1249265 .
Morillas-Arques P, Ma Rodriguez-Lopez C, Molina-Barea R, Rico-Villademoros F, Calandre EP. Trazodone for the treatment of fibromyalgia: An open-label, 12-week study. BMC Musculoskelet Disord. 2010;11:1–6. Available from: https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/1471-2474-11-204 .
Calandre EP, Morillas-Arques P, Molina-Barea R, Rodriguez-Lopez CM, Rico-Villademoros F. Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet Disord. 2011;12:95. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112435/ .
Krell HV, Leuchter AF, Cook IA, Abrams M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics. 2005;46:379–84.
doi: 10.1176/appi.psy.46.5.379
pubmed: 16145181
Arnold LM, Hirsch I, Sanders P, Ellis A, Hughes B. Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 2012;64:2387–97. https://doi.org/10.1002/art.34390 .
doi: 10.1002/art.34390
pubmed: 22275142
Konuk N, Ortancil O, Bostanci B, Kiran S, Sapmaz P. A comparison of reboxetine and amitryptilline in the treatment of fibromyalgia syndrome with co-morbid depressive symptoms: an open-label preliminary study. Klin Psikofarmakol Bülteni-Bull Clin Psychopharmacol. 2010;20:29–37. https://doi.org/10.1080/10177833.2010.11790631 .
doi: 10.1080/10177833.2010.11790631
Yeephu S, Suthisisang C, Suttiruksa S, Prateepavanich P, Limampai P, Russell IJ. Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. Ann Pharmacother. 2013 Jul-Aug;47(7-8):921-32. https://doi.org/10.1345/aph.1R725 .
Miki K, Murakami M, Oka H, Onozawa K, Yoshida S, Osada K. Efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase IIa study in Japan. Pain. 2016;157:2089. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988084/ .
Suttiruksa S, Yeephu S, Prateepavanich P, Suthisisang C. Effects of mirtazapine on quality of life of Thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial. Asian Biomed. 2016;10:435–45.
Mehta P, Basu A, Ahmed S. Effectiveness and adverse effects of the use of mirtazapine as compared to duloxetine for fibromyalgia: real-life data from a retrospective cohort. Rheumatol Int. 2022;42:1549–54. Available from: https://link.springer.com/article/10.1007/s00296-022-05135-y .
Welsch P, Bernardy K, Derry S, Moore RA, Häuser W. Mirtazapine for fibromyalgia in adults. Cochrane Database Syst Rev. 2018. https://doi.org/10.1002/14651858.CD012708.pub2 .
Stahl SM, Porreca F, Taylor CP, Cheung R, Thorpe AJ, Clair A. The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities? Trends Pharmacol Sci. 2013;34:332–9. Available from: https://pubmed.ncbi.nlm.nih.gov/23642658/ .
Malemud C. Focus on pain mechanisms and pharmacotherapy in the treatment of fibromyalgia syndrome. Clin Exp Rheumatol. 2009;27:S86–91.
pubmed: 20074446
Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–73. https://doi.org/10.1002/art.20983 .
doi: 10.1002/art.20983
pubmed: 15818684
Biçer GY, Zor KR, Biçer KE, Küçük E, Küçük EB. Can the long term using of pregabalin in fibromyalgia affect the choroid and retinal nerve fiber layer? Eye (Lond). 2022;36:2318–22. Available from: https://pubmed.ncbi.nlm.nih.gov/34857924/ .
Bidari A, Moazen-Zadeh E, Ghavidel-Parsa B, Rahmani S, Hosseini S, Hassankhani A. Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial. Daru. 2019;27:149–58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30877484 .
Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, et al. An international, randomized, double-blind, placebo-controlled,phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumat. 2011;38:2643–52. Available from: https://pubmed.ncbi.nlm.nih.gov/21965636/ .
Alciati A, Atzeni F, Masala IF, Cirillo M, Sciortino D, Perna G, et al. Controlled-release pregabalin in the treatment of fibromyalgia. Expert Rev Neurother. 2018;18:617–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30092164 .
Tong C, Zhengyao Z, Mei L, Dongpo S, Qian H, Fengqun M. Pregabalin and gabapentin in patients with spinal cord injury-related neuropathic pain: a network meta-analysis. Pain Ther. 2021;10:1497–509. Available from: https://link.springer.com/article/10.1007/s40122-021-00302-8 .
Cooper TE, Derry S, Wiffen PJ, Moore RA. Gabapentin for fibromyalgia pain in adults. Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd. 2017.
North JM, Hong K soo J, Rauck RL. The effect of a novel form of extended-release gabapentin on pain and sleep in fibromyalgia subjects: an open-label pilot study. Pain Pract. 2016;16:720–9. https://doi.org/10.1111/papr.12319 .
Littlejohn G, Guymer E. Modulation of NMDA receptor activity in fibromyalgia. Biomedicines. 2017;5:15. Available from: https://www.mdpi.com/2227-9059/5/2/15/htm .
Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, Bengtsson M, Sörensen J, Johnson A, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain. 2000;85:483–91.
doi: 10.1016/S0304-3959(99)00308-5
pubmed: 10781923
Noppers I, Niesters M, Swartjes M, Bauer M, Aarts L, Geleijnse N, et al. Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double blind, active placebo-controlled trial. Eur J Pain. 2011;15:942–9.
doi: 10.1016/j.ejpain.2011.03.008
pubmed: 21482474
Pastrak M, Abd-Elsayed A, Ma F, Vrooman B, Visnjevac O. Systematic review of the use of intravenous ketamine for fibromyalgia. Ochsner J. 2021;21:387–94. Available from: https://www.ochsnerjournal.org/content/21/4/387 .
Hanna AF, Smith AJ. Intravenous K-T relief in a patient with fibromyalgia. 2016. Available from: https://doi.org/10.4172/foa.1000104 .
Sharma S, Gupta R. Outpatient ketamine infusions for the treatment of fibromyalgia and chronic pain syndrome: a case report. 2023.
Javorcikova Z, Dangoisse M, Nikis S, Lechat JP, Gillain A, Fils JF, et al. The place of S-ketamine in fibromyalgia treatment (ESKEFIB): study protocol for a prospective, single-center, double-blind, randomized, parallel-group, dose-escalation controlled trial. Trials. 2021;22:1–11. Available from: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05814-4 .
Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum. 2004;51:9–13. Available from: http://doi.wiley.com/10.1002/art.20076 .
Moldofsky H, Harris HW, Tad Archambault W, Kwong T, Lederman S. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumat. 2011;38:2653–63. Available from: https://pubmed.ncbi.nlm.nih.gov/21885490/ .
Lederman S, Arnold LM, Vaughn B, Kelley M, Sullivan GM. Efficacy and safety of sublingual cyclobenzaprine for the treatment of fibromyalgia: results from a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2023. Available from: https://doi.org/10.1002/acr.25142 .
McLain D. An Open label dose finding trial of tizanidine [Zanaflex
doi: 10.1300/J094v10n04_02
Desai MJ, Saini V, Saini S. Myofascial pain syndrome: a treatment review. Pain Ther. 2013;2:21–36. Available from: https://link.springer.com/article/10.1007/s40122-013-0006-y .
Derry S, Wiffen PJ, Häuser W, Mücke M, Tölle TR, Bell RF, et al. Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults. Cochrane Database Syst Rev. 2017;2017. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012332.pub2/full .
Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta J-K. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27:10000–6. https://doi.org/10.1523/JNEUROSCI.2849-07.2007 .
doi: 10.1523/JNEUROSCI.2849-07.2007
pubmed: 17855614
pmcid: 6672650
Peng X, Robinson RL, Mease P, Kroenke K, Williams DA, Chen Y, et al. Long-term evaluation of opioid treatment in fibromyalgia. Clin J Pain. 2015;31:7–13. Available from: https://journals.lww.com/clinicalpain/fulltext/2015/01000/long_term_evaluation_of_opioid_treatment_in.2.aspx .
Jackson D, Singh S, Zhang-James Y, Faraone S, Johnson B. The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia. Front Psychiatry. 2021;12. Available from: https://pubmed.ncbi.nlm.nih.gov/33664680/ .
Hall OT, Teater J, Entrup P, Deaner M, Bryan C, Harte SE, et al. Fibromyalgia predicts increased odds of pain-related addiction exacerbation among individuals with pain and opioid use disorder. Pain. 2023;164:1801–9. Available from: https://journals.lww.com/pain/fulltext/2023/08000/fibromyalgia_predicts_increased_odds_of.17.aspx . This article is important because it provides the first evidence of fibromyalgia as a risk factor for pain-related exacerbation of opioid use disorder, and introduces a new, promising scale for measuring pain-related opioid use disorder exacerbation.
Diasso PDK, Abou-Kassem D, Nielsen SD, Main KM, Sjøgren P, Kurita GP. Long-term opioid treatment and endocrine measures in chronic non-cancer pain patients. Eur J Pain. 2023;27:940–51. https://doi.org/10.1002/ejp.1797 .
doi: 10.1002/ejp.1797
pubmed: 37243401
Song IA, Choi HR, Oh TK. Long-term opioid use and mortality in patients with chronic non-cancer pain: ten-year follow-up study in South Korea from 2010 through 2019. EClinicalMedicine. 2022;51. Available from: http://www.thelancet.com/article/S2589537022002887/fulltext .
Rivera J, Vallejo MA. Fibromyalgia is associated to receiving chronic medications beyond appropriateness: a cross-sectional study. Rheumatol Int. 2016;36:1691–9. Available from: https://link.springer.com/article/10.1007/s00296-016-3568-2 .
Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003;114:537–45.
doi: 10.1016/S0002-9343(03)00116-5
pubmed: 12753877
da Rocha AP, Mizzaci CC, Nunes Pinto ACP, da Silva Vieira AG, Civile V, Trevisani VFM. Tramadol for management of fibromyalgia pain and symptoms: systematic review. Int J Clin Pract. 2020;74:e13455. https://doi.org/10.1111/ijcp.13455 .
Cagle S, Bay D, Herndon C. What is the addictive potential of tramadol? Evidence-Based Pract. 2020;23:29–30. Available from: https://journals.lww.com/ebp/fulltext/2020/02000/what_is_the_addictive_potential_of_tramadol_.23.aspx .
Coluzzi F, Fornasari D, Pergolizzi J, Romualdi P. From acute to chronic pain: tapentadol in the progressive stages of this disease entity. Eur Rev Med Pharmacol Sci. 2017;21:1672–83.
pubmed: 28429337
FS Alshehri. Tapentadol: a review of experimental pharmacology studies, clinical trials, and recent findings. Drug Des Devel Ther. 2023;17:851–61 Available from: https://doi.org/10.2147/DDDT.S402362 .
van de Donk T, van Velzen M, Dahan A, Niesters M. Cornea nerve fibre state determines analgesic response to tapentadol in fibromyalgia patients without effective endogenous pain modulation. Eur J Pain. 2019;23:1586–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31162787 .
de Tommaso M, Vecchio E, Nolano M. The puzzle of fibromyalgia between central sensitization syndrome and small fiber neuropathy: a narrative review on neurophysiological and morphological evidence. Neurol Sci. 2022;43:1667–84. Available from: https://link-springer-com.pros1.lib.unimi.it/article/10.1007/s10072-021-05806-x .
Watanabe M, Maemura K, Kanbara K, Tamayama T, Hayasaki H. GABA and GABA Receptors in the central nervous system and other organs. Int Rev Cytol. 2002;213:1–47.
doi: 10.1016/S0074-7696(02)13011-7
pubmed: 11837891
Corrigan R, Derry S, Wiffen PJ, Moore RA. Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;2017. https://doi.org/10.1002/14651858.CD009486.pub2 .
Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76:318–28.
doi: 10.1136/annrheumdis-2016-209724
pubmed: 27377815
Peirce GL, Smith MJ, Abate MA, Halverson J. Doctor and pharmacy shopping for controlled substances. Med Care. 2012;50:494–500. Available from: https://pubmed.ncbi.nlm.nih.gov/22410408/ .
A. Brown M, Guilleminault C. A review of sodium oxybate and baclofen in the treatment of sleep disorders. Curr Pharm Des. 2011;17:1430–5. Available from: https://pubmed.ncbi.nlm.nih.gov/21476957/ .
Zhornitsky S, Potvin S, Moteshafi H, Dubreucq S, Rompré PP, Stip E. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol. 2011;26:183–92. Available from: https://journals.lww.com/intclinpsychopharm/fulltext/2011/07000/dose_response_and_comparative_efficacy_and.1.aspx .
López-Muñoz F, Álamo C. Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front Psychiatry. 2013;4:48288. Available from: www.frontiersin.org .
Hidalgo J, Rico-Villademoros F, Calandre EP. An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:71–7.
doi: 10.1016/j.pnpbp.2006.06.023
pubmed: 16889882
Potvin S, Morin M, Cloutier C, Gendron A, Bissonnette A, Marchand S. Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial. J Clin Psychopharmacol. 2012;32:684–7. Available from: https://journals.lww.com/psychopharmacology/fulltext/2012/10000/add_on_treatment_of_quetiapine_for_fibromyalgia__a.16.aspx .
McIntyre A, Paisley D, Kouassi E, Gendron A. Quetiapine fumarate extended-release for the treatment of major depression with comorbid fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. Arthritis Rheumat. 2014;66:451–61. https://doi.org/10.1002/art.38228 .
doi: 10.1002/art.38228
Calandre EP, Rico-Villademoros F, Galán J, Molina-Barea R, Vilchez JS, Rodriguez-Lopez CM, et al. Quetiapine extended-release (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16-week, randomized, flexible-dose, open-label trial. Psychopharmacology (Berl). 2014;231:2525–31. Available from: https://pubmed.ncbi.nlm.nih.gov/24398824/ .
Walitt B, Klose P, Üçeyler N, Phillips T, Häuser W. Antipsychotics for fibromyalgia in adults. Cochrane Database Syst Rev. John Wiley and Sons Ltd. 2016.
Freedenfeld RN, Murray M, Fuchs PN, Kiser RS. Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. Pain Pract. 2006;6:112–8. https://doi.org/10.1111/j.1533-2500.2006.00072.x .
doi: 10.1111/j.1533-2500.2006.00072.x
pubmed: 17309719
Rico-Villademoros F, Hidalgo J, Dominguez I, García-Leiva JM, Calandre EP. Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:161–4.
doi: 10.1016/j.pnpbp.2004.08.012
pubmed: 15610961
Grayson M. Cannabis. Nature. Outlook. 2015;525:2015.
Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. Nature Publishing Group; 2018. p. 623–39. Available from: https://pubmed.ncbi.nlm.nih.gov/30116049/ .
Pertwee RG. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9-tetrahydrocannabinol, cannabidiol and Δ 9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199–215.
doi: 10.1038/sj.bjp.0707442
pubmed: 17828291
Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, et al. A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis. 2018;24:714–24. Available from: https://pubmed.ncbi.nlm.nih.gov/29538683/ .
Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O’Sullivan SE. Palmitoylethanolamide and cannabidiol prevent inflammation-induced hyperpermeability of the human gut in vitro and in vivo-a randomized, placebo-controlled, double-blind controlled trial. Inflamm Bowel Dis. 2019;25:1006–18. Available from: https://pubmed.ncbi.nlm.nih.gov/31054246/ .
Hohmann AG, Suplita RL. Endocannabinoid mechanisms of pain modulation. Drug Addict Basic Res Ther. 2008;8:737–64.
doi: 10.1007/978-0-387-76678-2_44
Walitt B, Klose P, Ma F, Phillips T, Häuser W. Cannabinoids for fibromyalgia (Review). Cochrane Database Syst Rev. 2016.
Weber J, Schley M, Casutt M, Gerber H, Schuepfer G, Rukwied R, et al. Tetrahydrocannabinol (Delta 9-THC) Treatment in chronic central neuropathic pain and fibromyalgia patients: results of a multicenter survey. Blanck TJJ, editor. Anesthesiol Res Pract. 2009;2009:827290. Available from: https://doi.org/10.1155/2009/827290 .
Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V. Safety and efficacy of medical cannabis in fibromyalgia. J Clin Med. 2019;8:807.
doi: 10.3390/jcm8060807
pubmed: 31195754
pmcid: 6616435
Chaves C, Bittencourt PCT, Pelegrini A. Ingestion of a THC-rich cannabis oil in people with fibromyalgia: a randomized, double-blind, placebo-controlled clinical trial. Pain Med. 2020 [cited 2021 Jan 12];21:2212–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593796/report=abstract .
Hershkovich O, Hayun Y, Oscar N, Shtein A, Lotan R. The role of cannabis in treatment-resistant fibromyalgia women. Pain Pract. 2023;23:180–4. Available from: https://pubmed.ncbi.nlm.nih.gov/36333278/ .
Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023;382:44. Available from: https://www.bmj.com/content/382/bmj-2022-072348 .
Cao C, Li Q, Zhang X, Varrassi G, Wang H. Effectiveness of hyperbaric oxygen for fibromyalgia: a meta-analysis of randomized controlled trials. Clin Pract. 2023;13:583–95. Available from: https://pubmed.ncbi.nlm.nih.gov/37218804/ .
Almutairi NM, Hilal FM, Bashawyah A, Al Dammas F, Yamak Altinpulluk E, Hou J De, et al. Efficacy of acupuncture, intravenous lidocaine, and diet in the management of patients with fibromyalgia: a systematic review and network meta-analysis. Healthcare (Basel). 2022;10. Available from: https://pubmed.ncbi.nlm.nih.gov/35885703/ .